Last $16.82 USD
Change Today -0.10 / -0.59%
Volume 11.3M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$16.84
Previous Close
$16.92
Day High
$16.88
Day Low
$16.64
52 Week High
02/25/15 - $16.97
52 Week Low
10/16/14 - $11.10
Market Cap
22.4B
Average Volume 10 Days
18.0M
EPS TTM
$0.45
Shares Outstanding
1.3B
EX-Date
--
P/E TM
37.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Reportedly Close To Acquiring Endo AMS

Boston Scientific Corporation (NYSE: BSX) is close to buying American Medical Systems, Inc. from Endo International PLC (NasdaqGS:ENDP). The deal will value the business at around $2 billion, according to people familiar with the matter. The companies are aiming to finalize an agreement within a matter of weeks, the people said this week, cautioning that discussions are continuing and could still fall apart. The sources asked not to be named because the matter is not public. Reuters added that a representative for Boston Scientific declined to comment. A representative for Endo could not be reached for comment.

Boston Scientific to Pay $600 Million to Settle with Johnson & Johnson

Boston Scientific said it will pay $600 million to settle with Johnson & Johnson over the medical device maker's $27 billion acquisition of Guidant Corp. in 2006. Johnson & Johnson, which lost a bidding war for Guidant, Boston Scientific and Abbott Laboratories, accusing them of interfering with its Guidant deal. To avoid antitrust problems, Boston Scientific had sold Guidant's stent and vascular unit to Abbott for $4.1 billion plus a $900 million loan. Boston Scientific said that Johnson & Johnson had wanted $7 billion in damages but will dismiss its lawsuit. Under the settlement, Boston Scientific also won't sue Johnson & Johnson over several stent products.

Boston Scientific Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM

Boston Scientific Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Daniel J. Brennan, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $16.82 USD -0.10

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,901 JPY +3.00
Coloplast A/S kr530.00 DKK +2.00
Olympus Corp ¥4,335 JPY -70.00
St Jude Medical Inc $66.80 USD -0.19
Terumo Corp ¥3,300 JPY +45.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 85.4x
Price/Sales 3.0x
Price/Book 3.3x
Price/Cash Flow 31.8x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.